Life Sciences and Healthcare

GSK’s Shingrix set to become the market leading shingles vaccine

This article is part of an ongoing blog series profiling the twelve new, game-changing drugs predicted to achieve blockbuster status by 2022 in the 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics. Read the full Drugs to Watch report here or follow the series for latest updates. The […]

Reimbursement & regulations: cdm updates, cardiac device credits, and revenue code 456

Though you are hopefully already aware, on April 1, 2018, Medicare updated the Hospital Outpatient Prospective Payment System (OPPS). It is now paying for nonpass-through drugs, biologicals, and therapeutic radiopharmaceuticals that are not acquired through the 340B Program at the average sales price plus 6%. It is important to update your charge description master to […]

Women have their say as all-female panel talks biopharma investment, technology trends

This article is part of an ongoing series from Clarivate Analytics celebrating women in STEM with profiles of female scientists, inventors, researchers, and corporate leaders featured in BioWorld, Derwent, Web of Science, and Publons. See more articles in this series, or follow our online campaign using #WomenAtClarivate. One of the hottest tickets in town during […]

Oncology, driven by the promise of IO, dominates biopharma deals landscape

Spurred by the promise of immuno-oncology (IO), oncology dominated the biopharma dealmaking landscape last year, a new article by Jamie Munro and Helen Dowden, of Clarivate Analytics, shows. The acute interest in IO continues a trend, the article noted: The technology has been a factor in 32 of the 35 multibillion-dollar oncology licensing deals over […]

The opioid crisis: a 21st century pain

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered from Clarivate Analytics Cortellis.   The pain market Due to the significant healthcare and economic […]

Fast-forward: Larry Liberti on the evolving landscape of pharma regulation

  Larry Liberti has served as executive director of the Centre for Innovation in Regulatory Science (CIRS) since 2009. In that capacity, he has been actively involved in promoting best practices in the regulatory aspects of the development of medicines, especially in the emerging markets. He has worked in the fields of pharmaceutical regulatory affairs, […]

Changing product mix, shifting geography drive sourcing and manufacturing outlook

Manufacturing (supply) and sourcing (demand) are very much intertwined. In an industry where scaling up manufacturing or getting approvals to use a new supplier can take several months, if not years, it is critical to anticipate future needs. It is clear that one area to watch in biopharma sourcing and manufacturing is the changing product […]

With Cigna–Express Scripts, last PBM domino falls

The last pharmacy benefit management giant waiting for a potential suitor is off the board now that Cigna and Express Scripts plan a $67 billion merger. For Express Scripts, the last of the large independent PBMs, a merger with Cigna makes sense. Express Scripts was in a bind. After an ugly divorce, Express Scripts lost […]